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Despite extensive childhood immunisation, pertussis 
remains one of the world’s leading causes of vaccine-
preventable deaths. The current methods used for 
laboratory diagnosis of pertussis include bacterial 
culture, polymerase chain reaction (PCR) and enzyme-
linked immunosorbent assay (ELISA) serology. We con-
ducted a questionnaire survey to identify variations in 
the laboratory methods and protocols used among 
participating countries included in the European sur-
veillance network for vaccine-preventable diseases 
(EUVAC.NET). In February 2010, we performed the sur-
vey using a web-based questionnaire and sent it to 
the country experts of 25 European Union countries, 
and two European Economic Area (EEA) countries, 
Norway and Iceland. The questionnaire consisted of 
37 questions which covered both general informa-
tion on surveillance methods and detailed laboratory 
methods used. A descriptive analysis was performed. 
Questionnaires were answered by all 27 contacted 
countries. Nineteen countries had pertussis reference 
laboratories at the national level; their functions var-
ied from performing diagnosis to providing technical 
advice for routine microbiology laboratories. Culture, 
PCR and serology were used in 17, 18 and 20 countries, 
respectively. For PCR, nine laboratories used insertion 
sequence IS481 as the target gene, which is present 
in multiple copies in the Bordetella pertussis genome 
and thus has a greater sensitivity over single copy 
targets, but has been proved not to be specific for B. 
pertussis. Antibodies directed against pertussis toxin 
(PT) are specific for B. pertussis infections. For ELISA 
serology, only 13 countries’ laboratories used purified 
PT as coating antigen and 10 included World Health 
Organization (WHO) or Food and Drug Administration 
(FDA) reference sera in their tests. This present survey 
shows that methods used for laboratory confirmation 
of pertussis differ widely among European countries 
and that there is a great heterogeneity of the reference 
laboratories and functions. To evaluate the effects 
of different pertussis immunisation programmes in 
Europe, standardisation and harmonisation of the lab-
oratory methods are needed.
Introduction
Bordetella pertussis is an exclusive human pathogen 
which causes whooping cough or pertussis. Before the 
introduction of childhood vaccination, pertussis was 
a major cause of infant deaths in the world including 
Europe [1-4]. However, despite the extensive vaccina-
tion, pertussis has remained endemic [1-4]. The dis-
ease has resurged in the last decade and remains the 
least controlled of vaccine-preventable disease world-
wide [5-13]. 
Surveillance of pertussis in European countries
Within Europe, the reported incidences vary widely. 
In 2010, the highest rate (97/100,000) was reported 
in Norway and zero cases were reported from Cyprus, 
Iceland and Luxemburg [14]. Data collected by the 
European surveillance network for vaccine-preventa-
ble diseases (EUVAC.NET) from 28 European countries 
conducting surveillance on whole population showed a 
stable number of pertussis cases in the period 2003–
10, and an increase in incidence in adolescents [14]. In 
France, where pertussis surveillance at whole-popula-
tion level is complemented by surveillance in infants 
below the age of six months in selected hospitals, a 
national incidence of 276/100,000 in 0–2 month-old 
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infants was extrapolated for the period 1996–2005 [7]. 
This epidemiological picture underlines the need for 
both better surveillance and control of the disease and 
careful interpretation of the surveillance data.
Surveillance of 47 diseases and two health conditions 
is mandatory in the European Union (EU) and European 
Economic Area/European Free Trade Association (EEA/
EFTA) countries and EU case definitions should be 
used for reporting [15]. Pertussis is included among 
those diseases [16]. The case definition includes clini-
cal, epidemiological and laboratory criteria. However, 
laboratory procedures and completeness of reporting 
may differ between countries and through time, and 
therefore direct comparability of laboratory-confirmed 
or clinically-diagnosed cases across Europe, and 
between years cannot be assumed. Laboratory con-
firmation is always warranted when there is a clinical 
suspicion of pertussis, because atypical symptoms 
often occur in infants, vaccinated adolescents and 
adults. Furthermore, co-infections with other microbial 
pathogens have been reported [17,18], and no clinician 
can differentiate symptoms caused by B. pertussis and 
other Bordetella species such as B. parapertussis [1].
Laboratory methods to diagnose 
pertussis in European countries
At present, the laboratory methods available to diag-
nose pertussis include bacterial culture, polymerase 
chain reaction (PCR) and enzyme-linked immunosorb-
ent assay (ELISA) serology.
Culture is the basic method for the diagnosis of per-
tussis. The specimen collection for the bacterial testing 
is a critical part of the diagnosis. Because B. pertussis 
binds to the ciliated epithelial cells of the human upper 
respiratory tract, that are found in the nasopharynx, 
culture specimens should be taken from the posterior 
nasopharynx, either by nasopharyngeal (NP) swabs or 
aspiration. Calcium alginate, dacron and rayon swabs 
can be used. Because B. pertussis is a fragile bacte-
rium, NP swabs or aspirates should be sent to the 
laboratory within four hours of collection, at room tem-
perature. The swab or the tip of the catheter can also be 
placed in Reagan–Lowe transport medium. The other 
critical part for a successful diagnosis based on culture 
is an accurate identification of bacterial species.
Polymerase Chain Reaction (PCR) has proved to be 
more sensitive and faster than culture. Its advan-
tages over culture include detecting bacterial nucleic 
acid fragments from both dead and viable bacteria. 
Specimens for PCR should be taken from the poste-
rior nasopharynx by NP swab or aspiration. Dacron or 
rayon swabs are recommended, whereas swabs made 
of cotton or calcium alginate are not suitable. Insertion 
sequence IS481, pertussis toxin promoter region (ptxA-
Pr) and porin gene can be used as amplification tar-
gets in PCR for B. pertussis. Since porin can be found in 
other bacteria, a positive PCR result is not specific for 
B. pertussis. The most frequently used target gene is 
IS481 because of its high copy number in the genome of 
B. pertussis. However, the IS481-based PCR is not 
able to differentiate B. pertussis from B. holmesii and 
B. bronchiseptica [19,20]. Compared to IS481 PCR, the 
ptxA-Pr based PCR is found to be specific for B. pertus-
sis but is less sensitive due to its single copy number 
in the genome of B. pertussis. A positive result for both 
IS481 and ptxA-Pr based PCRs can be considered as a 
definite B. pertussis infection. 
In terms of serological tests, those detecting IgG anti-
bodies to purified pertussis toxin (PT) are the most 
specific for B. Pertussis, so PT is recommended as a 
coating antigen in both in house ELISA and commercial 
kits [21-23]. 
Both culture and PCR are suitable diagnosis methods 
during the early stage of the disease (i.e., < 3 weeks 
of onset), making them more suitable for children and 
infants with severe disease [21]. Enzyme-linked immu-
nosorbent assay serology has shown to be useful for 
the late stage of disease (i.e., > 3 weeks of onset), 
especially in older children and adults, who may seek 
healthcare treatment later due to a milder clinical 
presentation, and for whom the higher maturity of the 
acquired immune system allows more reliable ELISA 
results [21]. It is known that many factors can affect 
specificity and sensitivity of these methods [24]. In 
many laboratories, PCR and ELISA serology used are 
usually validated in-house and therefore results are 
not comparable across laboratories. There is also con-
siderable variation in criteria necessary for validation. 
Methods to identify the bacteria in bacterial culture 
can also differ between laboratories. 
Aims of the study
EUVAC.NET was a European surveillance network for 
vaccine preventable diseases, based at the Statens 
Serum Institut, Copenhagen, Denmark. From September 
2011, the coordination of the activities was transferred 
to the European Centre for Disease Prevention and 
Control (ECDC), Stockholm, Sweden. EUVAC.NET activi-
ties included epidemiological surveillance of pertussis 
and the development of laboratory-based surveillance 
of pertussis. This study was part of the latter activity. 
The aims were to identify the availability of pertussis 
reference laboratories established in respective EU 
and EEA/EFTA countries and the functions of these lab-
oratories, and to identify and describe methods used 
for laboratory confirmation of pertussis.
Methods
Design of the survey
A questionnaire was designed by the European 
Bordetella expert (EUpertstrain) group in collabora-
tion with the EUVAC.NET hub. The EUpertstrain group 
consists of representatives of the Bordetella reference 
laboratories in their respective EU countries [21].
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Countries participating in the survey
As part of the EUVAC.NET activities to develop labora-
tory-based surveillance in EU member states, a group 
of laboratory experts on pertussis was included in 
the network in 2010. In this manuscript this group is 
referred to as pertussis country experts. The experts 
were appointed by national health authorities as 
requested by the ECDC. As of February 2010, 25 EU 
countries and two EEA countries, Norway and Iceland, 
had identified one respective expert. Bulgaria, Cyprus 
and Latvia identified two experts. All pertussis coun-
try experts were invited and agreed to respond to the 
questionnaire.
Data collection and analysis
The web-based questionnaire consisted of 37 specific 
questions. The questionnaire covered general infor-
mation and asked about the existence of a national 
reference laboratory for pertussis and its function. 
Questions on detailed laboratory methods used for 
the diagnosis of pertussis were also included. Of the 
37 questions, 25 required single answer, nine required 
multiple answers and three required description. Data 
was analysed in a descriptive way. 
This study was funded by ECDC, Statens Serum Institut 
(Denmark) and National Institute for Health and Welfare 
(Finland). Sponsors of this study had no role in study 
design, data collection, data analysis, data interpreta-
tion, or writing of the report. The summary of the find-
ings and the manuscript was approved by the country 
experts before submission.
Results
All of the contacted countries responded (27/27), such 
that the response rate to the survey was 100%.
Reference laboratories and their 
functions at national level
Nineteen of 27 countries stated to have pertussis refer-
ence laboratories at the national level, whereas eight 
countries did not (Table 1). 
An inventory of a reference laboratory’s functions was 
not available at the time the survey was undertaken, 
accordingly we asked the countries to list the functions 
in a descriptive manner. Thereafter, the reference func-
tions were categorised as following: diagnosis, bacte-
rial typing, surveillance and technical advice for routine 
microbiology laboratories (Table 2). Fourteen of 19 
countries’ laboratories had responsibility for diagno-
sis, seven for surveillance and 11 for technical advice. 
Only eight reference laboratories performed bacte-
rial typing, an important method to monitor emerging 
B. pertussis strains as well as to compare vaccine anti-
gens to bacterial antigens in circulating isolates. Of the 
19 reference laboratories, twelve laboratories had two 
functions, three laboratories had three functions, and 
the laboratory for England had all four functions. Of 
the 12 laboratories having at least two functions, only 
three had both functions for diagnosis and bacterial 
typing. 
Estimated number of laboratories 
performing pertussis diagnostics
Among countries, the number of estimated labora-
tories performing pertussis diagnostics per country 
varied a lot. Two countries (Hungary and Luxembourg) 
table 1
Presence or absence of pertussis reference laboratories in 
EU and EEA/EFTA countries, 2010 (n=27)
Reference 
laboratory
Number of 
countries Countries
Absent 8
Cyprus, Estonia, Greece, 
Iceland, Ireland, Lithuania, 
Malta and Poland
Present 19
Austria, Belgium, Bulgaria, 
Czech Republic, Denmark, 
England, Finland, France, 
Germany, Hungary, Italy, Latvia, 
Luxembourg, Netherlands, 
Norway, Romania, Slovakia, 
Slovenia and Sweden
EEA: European Economic Area; EFTA: European Free Trade 
Association; EU: European Union.
table 2
Functions of the pertussis reference laboratories, in the 
countries (n=19) where a pertussis reference laboratory is 
present, EU and EEA/EFTA countries, 2010
Functions of the 
pertussis reference 
laboratories
Number of 
countries Countries
Diagnosis 14
Austria, Belgium, Bulgaria, 
Cyprus, Czech Republic, 
Denmark, England, 
Germany, Hungary, Latvia, 
Luxembourg, Netherlands, 
Romania and Slovakia
Bacterial typing 8
Austria, Belgium, 
England, Finland, France, 
Netherlands, Norway and 
Sweden 
Surveillance 7
Denmark, England, 
Hungary, Italy, Latvia, 
Norway and Romania
Technical advice 11
Czech Republic, England, 
Finland, France, Germany, 
Hungary, Italy, Norway, 
Romania, Slovakia and 
Sweden 
EEA: European Economic Area; EFTA: European Free Trade 
Association; EU: European Union. 
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had only one respective laboratory performing pertus-
sis diagnostics. Thirteen countries (Austria, Belgium, 
Bulgaria, Cyprus, Denmark, Finland, Greece, Iceland, 
Ireland, Latvia, Lithuania, Malta and Slovenia) had less 
than 10; four countries (Estonia, Norway, Slovakia and 
Sweden) had 10 to 30; three countries (Czech Republic, 
Italy and the Netherlands) had from 30 to 100; and 
three countries (England, France and Germany) had 
more than 100. The number of estimated laboratories 
was not known in Romania and Poland. 
Laboratory methods for diagnosis of pertussis
When the laboratory methods for diagnosis of pertus-
sis were surveyed, 17 countries had laboratories per-
forming culture, 18 PCR and 20 ELISA (Table 3).
Culture
In the reference laboratories of 17 countries, culture 
was performed for diagnosis (Table 3). In 10 countries 
both NP aspirates and swabs were accepted as speci-
mens by laboratories, in six countries (Czech Republic, 
Latvia, Lithuania, Malta, Romania and Slovenia) only 
swabs were accepted, and in one country (Greece) only 
aspirates. A dacron swab for sampling was the most 
common type. Although cotton wool swabs are not 
recommended, these were utilised in three countries. 
The common media used for culture were Regan–Lowe 
and Bordet–Gengou (either medium in 7 countries and 
both in 2). For bacterial identification, specific meth-
ods were used in 12 countries and PCR was performed 
in five (Austria, Bulgaria, Luxembourg, Slovakia and 
Slovenia). In Greece, only gram stain was performed for 
bacterial identification and in Romania only biochemi-
cal characters were analysed (e.g. oxidase and urease). 
Polymerase chain reaction
According to our survey, 18 countries had laboratories 
using PCR (Table 3). Twelve countries had laboratories 
using real-time PCR, whereas five (Belgium, Bulgaria, 
Denmark, Finland and Hungary) had laboratories using 
block-based PCR. In Estonia both types of PCR were in 
use. The most common instrument used for real-time 
PCR was the LightCycler (Roche). The preferred sam-
ple type for PCR was a NP swab in four countries, NP 
aspirate in two countries, or both in 11 countries. The 
following NP swabs were used: dacron in seven coun-
tries, rayon in four countries and nylon (copan) in two 
countries. Solubilisation of the samples before deoxy-
ribonucleic acid (DNA) extraction was applied in 12 
countries. For DNA extraction, a commercial kit was 
used in 17 countries and a respective in house prepara-
tion in one (Denmark). Among commercial DNA extrac-
tion kits, the Qiagen kit was used in 11 countries and 
other kits (AmpliSens, Argene, Biomerieux, Chemagen 
and Roche) were used in six countries. Of the 18 coun-
tries where PCR was employed, 15 had laboratories 
using extraction control (water or PBS) alongside the 
real sample to check for contamination. Laboratories in 
Czech Republic, Iceland and Italy did not have any such 
controls.
Of the target genes used in B. pertussis PCR, IS481 was 
used in 14 of 18 countries’ laboratories (Table 4). The 
PCR targeting IS481 was the sole assay in eight coun-
tries’ laboratories while six countries had laboratories 
using this PCR in combination with a PCR targeting the 
ptxA-Pr. The laboratories in Bulgaria and Luxembourg 
had ptxA-Pr and porin gene as targets, respectively. 
Ten countries’ laboratories used internal probes to con-
firm the amplified PCR products. For ten countries, the 
PCR reaction had a volume of 20 μl, for four (Belgium, 
Estonia, France and Ireland) 25 μl, for one (Finland) 
50 μl, and for three (Czech Republic, Denmark and 
Germany) other reaction volumes not indicated above. 
In all of the 18 countries’ laboratories both positive 
and negative controls in each PCR run were included. 
However, only in nine countries was an extraction 
control done, and in seven, an internal amplification 
control, to check for the presence of inhibitors in the 
extracted DNA.
Of the 18 countries whose laboratories performed PCR 
for detection of B. pertussis, 16 also did PCR for detec-
tion of B. parapertussis. Insertion sequence IS1001 
was used in laboratories in 13 countries, either as sole 
assay in nine countries, or in combination with ptxA-Pr 
in France and Germany, to confirm B. parapertussis. 
Enzyme-linked immunosorbent assay serology
table 3
Methods to laboratory confirm a pertussis case in EU and 
EEA/EFTA countries, 2010 (n=27)
Method to 
confirm a 
pertussis case
Number of 
countries Countries
Culture 17
Belgium, Czech Republic, 
Denmark, Finland, France, 
Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, 
Lithuania, Malta, Romania, 
Slovakia, Slovenia
PCR 18
Austria, Belgium, Bulgaria, 
Czech Republic, Denmark, 
England, Estonia, Finland, 
France, Germany, Greece, 
Hungary, Iceland, Ireland, 
Italy, Luxembourg, Slovakia, 
Slovenia
ELISAa 20
Austria, Belgium, Czech 
Republic, Cyprus, Denmark, 
England, Estonia, Finland, 
France, Germany, Greece, 
Hungary, Latvia, Lithuania, 
Netherlands, Norway, Poland, 
Romania, Slovakia, Slovenia
ELISA: enzyme-linked immunosorbent assay; EEA: European 
Economic Area; EFTA: European Free Trade Association; EU: 
European Union; PCR: polymerase chain reaction.
a  In Italy, ELISA was implemented for diagnosis after the 
questionnaire survey was done; and in Sweden, ELISA is used 
for seroepidemiology studies.
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Altogether, ELISA serology was performed for diag-
nosis in the laboratories of 20 countries (Table 3). 
Of these, 13 used single serum testing and 11 paired 
serology. In two countries (Denmark and Romania), 
laboratories performed paired serology only if the first 
sample indicated no evidence of pertussis infection. 
In thirteen countries, laboratories used purified PT as 
coating antigen in ELISA, in three countries commercial 
kits were used, in two (Finland and Greece) whole-cell 
bacteria, in one (Slovenia) filamentous haemagglutinin 
(FHA), and in one (Czech Republic) the coating antigen 
was not defined (Table 5). Only in six countries did 
laboratories use the World Health Organization (WHO) 
international reference sera [25] and in four the Food 
and Drug Administration (FDA) reference sera (Table 
5) [26]. In each run of the ELISA, laboratories in 12 
countries had both in house positive and negative con-
trol sera included, in three countries (Belgium, Czech 
Republic and Germany) only in-house positive control 
sera were present, in one country (Poland) only buffer, 
and in three countries (Estonia, Norway and Slovenia) 
controls were not specified. 
For the antibody class measured in ELISA, 19 coun-
tries’ laboratories tested for IgG, 17 for IgA and 12 for 
IgM. The ELISA units of the test serum calculated were 
based on: (i) comparison of the response curve of the 
test serum to that of the reference sera in laboratories 
table 4
Targeted genes by polymerase chain reaction for diagnosis of pertussis, EU and EEA/EFTA countries, 2010 (n=27)
Country
Polymerase chain reaction target genesa
IS481 PtxA–Pr IS481 and ptxA–Pr Porin
Austria Yes No No No
Belgium Yes No No No
Bulgaria No Yes No No
Cyprus – – – –
Czech Republic No No Yes No
Denmark Yes No No No
England No No Yes No
Estonia ND ND ND ND
Finland Yes No No No
France No No Yes No
Germany No No Yes No
Greece Yes No No No
Hungary No No Yes No
Iceland ND ND ND ND
Ireland No No Yes No
Italy Yes No No No
Latvia – – – –
Lithuania – – – –
Luxembourg No No No Yes
Malta – – – –
Netherlands – – – –
Norway – – – –
Poland – – – –
Romania – – – –
Slovakia Yes No No No
Slovenia Yes No No No
Sweden – – – –
Total 8 1 6 1
EEA: European Economic Area; EFTA: European Free Trade Association; EU: European Union; ND: not defined; ptxA–Pr: pertussis toxin 
promoter.
In the table, ‘yes’ indicates ‘used’, ‘no’ indicates ‘not used’ and ‘–‘ indicates ‘not performed’.
a  In a single assay, which can be either a reaction targeting one gene, or a reaction targeting two genes simultaneously.
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table 5
Coating antigens and standard sera used in ELISA for diagnosis of pertussis, EU and EEA/EFTA countries, 2010 (n=27)
Country
ELISA
Coating antigen Standard sera
PT Kita Othersb WHO FDA Othersc
Austria No Yes No No No Yes
Belgium Yesd No No Yes No No
Bulgaria – – – – – –
Cyprus Yesd No No Yes No No
Czech Republic No No Yes No No Yes
Denmark Yes No No Yes No No
England Yes No No Yes No No
Estonia No Yes No No No Yes
Finland No No Yes No No Yes
France Yes No No Yes No No
Germany Yese No No Yes No No
Greece No No Yes No No Yes
Hungary Yes No No No Yes No
Iceland – – – – – –
Ireland – – – – – –
Italy – – – – – –
Latvia Yes No No No Yes No
Lithuania Yes No No No Yes No
Luxembourg – – – – – –
Malta – – – – – –
Netherlands Yesf No No No Yes No
Norway No Yes No No No Yes
Poland Yes No No No No Yes
Romania Yes No No No No Yes
Slovakia Yes No No No No Yes
Slovenia No No Yes No No Yes
Sweden – – – – – –
Total 13 3 4 6 4 10
ELISA: enzyme-linked immunosorbent assay; EEA: European Economic Area; EFTA: European Free Trade Association; EU: European Union;  
FDA: Food and Drug Administration; FHA: filamentous haemagglutinin; PT: pertussis toxin; prn: pertactin; WHO: World Health Organization.
In the table, ‘yes’ indicates ‘used’, ‘no’ indicates ‘not used’ and ‘–‘ indicates ‘not performed’.
a For kits the coating antigen is not specified.
b Includes FHA, pertactin, whole bacteria or not defined.
c Includes in-house controls or not defined.
d Both PT and FHA are used.
e Both PT and prn are used.
f For IgG: PT is used; for IgA: whole bacteria is used.
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of eight countries, (ii) comparison of the absorbance of 
the test serum to that of the in-house positive human 
sera in laboratories of two countries, (iii) comparison of 
the absorbance of the test serum to that of a response 
curve of the in-house positive human sera in laborato-
ries of two countries, or (iv) other alternatives in labo-
ratories of eight countries. The cut-off values used to 
define recent pertussis infection were >100 IU/ml for 
IgG-anti PT (referred to the WHO international refer-
ence sera) in France, Lithuania and Romania; >50 IU/ml 
for IgG-anti PT and >12 IU/ml for IgA-anti PT in Austria, 
Cyprus and Latvia; and other criteria in 14 countries.
Discussion
We performed a survey among 27 EUVAC.NET partici-
pating countries and found a significant variation in 
the procedures used to confirm B. pertussis infection.
In this study, the participants were the country experts 
for pertussis appointed by the health authorities of 
the respective countries, and therefore the answers 
most likely reflect the situation of pertussis diagno-
sis in their countries. However, only up to two experts 
per country were included in this network, with one 
expert for most countries (24 of 27) and therefore the 
answers were probably related to the laboratory of his/
her affiliation. In larger countries or in countries where 
pertussis diagnosis is performed by more than one lab-
oratory, this might have contributed to a less accurate 
description.
Having and sustaining a reference laboratory is a criti-
cal part of laboratory-based surveillance and quality 
control. In this present survey, we found that only 19 
countries had pertussis reference laboratories at the 
national level. Routine primary diagnosis was found 
to be the main function among the reference labora-
tories. Only eight reference laboratories performed 
bacterial typing. Bacterial typing is perhaps the most 
specific and important function of the reference labo-
ratories. Indeed, marked changes have been found in 
the B. pertussis population and differences have been 
observed between vaccine strains and circulating iso-
lates [3,4]. It is important to monitor emerging B. per-
tussis strains. This is especially important for Europe 
since almost all European countries have changed from 
whole cell vaccines to acellular vaccines. Acellular 
vaccines contain only one to five antigens. Variations 
between vaccine strains and current circulating iso-
lates have been found in four of the five antigens [3,4]. 
Further, a new, more virulent B. pertussis lineage (des-
ignated P3 lineage) has been recently described and 
has spread worldwide [27]. The P3 lineage now pre-
dominates in many European countries and its emer-
gence was found to be associated with increased 
notifications in the Netherlands. Moreover, in France, 
where the surveillance of clinical isolates has been 
performed since 1990 and where acellular vaccines 
have been introduced since 1998 regular increased 
isolation of B. pertussis without expression of vaccine 
components is observed since 2006 [28]. B. pertussis 
isolate without expression of pertactin (Prn) was also 
reported in Italy [29]. This observation demonstrates 
the importance of microbial surveillance in order to fol-
low the effectiveness of the pertussis vaccines used in 
the field. It is then of high importance to monitor the 
expression of vaccine antigens in currently circulat-
ing isolates. Another noteworthy phenomenon is the 
increased reporting of pertussis-like disease caused 
by other Bordetella species such as B. holmesii [30,31]. 
This is important because B. holmesii can cause false 
positivity in IS481-based PCR most commonly used 
for detection of B. pertussis. Therefore, the capacity 
by a reference laboratory to perform bacterial typing 
remains essential to monitor emerging isolates or spe-
cies, and to inform and guide vaccine development and 
vaccination policies.
It is difficult to evaluate what functions each reference 
laboratory should have. Ideally, however, a national 
reference laboratory should be capable to carry out 
bacterial typing, diagnosis, surveillance and provide 
and disseminate technical advice. The technical advice 
should also include training of personnel who perform 
routine diagnosis in clinical microbiology laboratories, 
making data and laboratory diagnostic criteria compa-
rable at the national level. In an ECDC published report 
on ‘Core functions of microbiology reference labora-
tories for communicable diseases’, the core functions 
were identified as: (i) reference diagnostics, (ii) ref-
erence material resources, (iii) scientific advice, (iv) 
collaboration and research, (v) monitoring, alert and 
response [32]. These functions are partially overlap-
ping and elaborate further on the functions identified 
in our survey. Our assessment offered the opportunity 
to confirm that there is need to disseminate informa-
tion with the functions suggested and implement them 
across Europe. This will require a coordinated approach 
and both technical and political commitment. 
Culture has been the basic tool for the diagnosis of 
pertussis, although PCR and ELISA serology are the 
main diagnostic methods today. In this present study, 
throat swab is still in use for culture in one country, 
and non-specific methods are used for bacterial iden-
tification in two countries. It should be kept in mind 
that bacterial culture is important not only for diagno-
sis but also for continuous monitoring of emerging B. 
pertussis antigenic variants and of antimicrobial resist-
ant strains [33,34]. Therefore, performing bacterial cul-
tures in diagnostic laboratories should be encouraged. 
In this study, a wide variation was observed in meth-
ods and protocols for PCR. Guidelines for B. pertussis 
PCR methods are needed across Europe to ensure accu-
rate diagnosis of pertussis as well as other Bordetella 
infections.
The development of ELISA serology in the early 1980s 
allowed a new understanding of pertussis epidemiol-
ogy. In vaccinated older children, adolescents and 
adults, pertussis is a rather common infection and is 
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usually not suspected before they have had cough for 
several weeks [1,2]. Culture and PCR are then often 
negative but many of the patients can be diagnosed by 
single-point ELISA serology. Indeed, of the 6,876 labo-
ratory-confirmed cases in Finland from 1999 to 2006, 
82% were diagnosed by serology and 18% by culture 
and PCR [35]. Most of the young patients, less than 
two years of age, were diagnosed by culture and PCR, 
whereas the older patients were more often diagnosed 
by serology. This increasing use of serology testing 
is likely, at least in part, to have influenced reported 
increases in pertussis in adolescents and adults: 
previously these cases were not being confirmed. In 
Norway, a total of 49,052 pertussis cases were notified 
from March 1996 to October 2010 [36]. About 80,000 
to 90,000 pertussis tests were performed each year, 
resulting in about 5% positivity rate. Serology was 
frequently used throughout the entire time period 
and about 65–70% of the reported cases were diag-
nosed by serology. Some of the serology tests were 
in young children who had recently been vaccinated, 
thereby potentially leading to false positive diagno-
ses. Moreover, serological diagnostic cut-offs used 
were not standardised among counties, nor were they 
consistent through time. All of the facts mentioned 
above may contribute to the high incidence reported in 
Norway. For countries with low incidence rates, factors 
may include the level of awareness of the disease in 
clinicians and/or lack of laboratory diagnostic tests. 
Because serological tests detecting IgGs to purified 
PT are the most specific for B. pertussis, PT is recom-
mended as a coating antigen in ELISA [21]. In the pre-
sent study, only 13 of the 20 countries’ laboratories 
performing serology used PT as the coating antigen. 
When the performance of 11 ELISA kits commercially 
available in Europe was recently compared by a German 
group [22], the study clearly shows that kits with puri-
fied PT as an antigen should be used and IgG antibod-
ies to PT should be measured.
For the serological diagnosis, a significant increase 
in anti-pertussis antibodies between the paired sera 
would be the most reliable method. However, many 
patients do not consult a physician until they have 
had symptoms for several weeks, and the first serum 
is often taken too late to detect a significant increase 
in a second sample. Therefore, the single-point ELISA 
serology is commonly used and in clinical practice, 
one-point serology is a diagnostic tool with interpreta-
tion difficulties due to lack of standardisation. In this 
present study, more than 60% of countries’ laborato-
ries performing serology used single serum testing. 
However, only 32% of the laboratories included the 
WHO international reference sera in their ELISA [25]. 
Obviously, the cut-off values used to define recent 
pertussis infection in many of these laboratories were 
not based on the WHO international reference sera. 
Furthermore, a number of these laboratories still meas-
ured anti-pertussis IgA and IgM antibodies, which have 
been proved to be less specific and sensitive [1,2,22]. 
The number of laboratories performing pertussis diag-
nostics varied among the countries. About half of the 
countries reported less than 10 laboratories perform-
ing pertussis diagnosis, whereas three countries had 
even more than 100 such laboratories. Since about half 
of countries have a small number of pertussis diagnos-
tic laboratories, it might be possible to standardise the 
laboratory methods by means of organising training 
workshops among these countries first.
Clearly, small countries, in terms of population num-
ber, might not be able to offer all diagnostic services. 
Since infants may have severe and life-threatening 
illness due to pertussis, the order of importance for 
surveillance should be infants, children and adults. 
As recommended by the European Bordetella expert 
group EUpertstrain [21], PCR and/or culture should 
be performed in neonates and infants. Therefore, the 
diagnostic service with rapid real-time PCR should be 
considered.
This present survey clearly demonstrates that the 
methods and protocols used for laboratory confirma-
tion largely differ among European countries and that 
there is a need for standardisation and harmonisation 
of the laboratory methods in Europe. Furthermore, sur-
veillance reporting laboratory-confirmed cases via a 
European case definition will be much more valuable if 
laboratory methods are comparable. The survey high-
lighted that there is a need to implement and organ-
ise the functions of the European National reference 
laboratories. After the present survey, we organised 
two external quality assurance (EQA) studies to assess 
performance of the in-house PCR and ELISA for diag-
nosis of pertussis used in these reference laboratories 
within the EU [23,37]. Data from the two EQA studies 
confirmed the results obtained from this questionnaire 
survey. Since it is a big challenge for an EU-wide stand-
ardisation and harmonisation of laboratory methods 
for diagnosis of pertussis, the following steps should 
be considered: (i) to establish consensus protocols for 
both PCR and serology; (ii) to set up a reference labora-
tory or functions in each country and do standardisa-
tion first in the reference laboratories; and (iii) to have 
reference laboratories in each country in turn conduct 
standardisation among diagnostic laboratories. The 
EUpertstrain group consists of 12 pertussis reference 
and research laboratories within 10 European countries 
(see appendix). Because the third step is critical, it is 
important to set up some European pertussis reference 
centres, e.g. among the EUpertstrain group. The refer-
ence centres may help the national reference laborato-
ries across Europe to organise regular workshops and 
carry out EQA survey at national level.
This present survey shows that the methods used 
for laboratory confirmation of pertussis differ widely 
among European countries and that there is a great 
heterogeneity of the reference laboratories and in their 
functions. To evaluate the effects of different pertussis 
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immunisation programmes in Europe, coordinated 
activities for laboratory-based surveillance are needed 
for the European diagnostic laboratories. The activities 
should include standardisation of real-time PCR meth-
ods for detection of the genus Bordetella (in particu-
lar B. pertussis), standardisation of ELISA methods for 
determination of IgG anti-PT antibodies, and regular 
EQA studies for the diagnostic methods. Besides being 
important from the infectious disease surveillance per-
spective, standardisation and harmonisation of meth-
ods would be beneficial for the clinical diagnosis in 
terms of both specificity and sensitivity. In addition, 
long-term molecular surveillance of B. pertussis circu-
lating isolates across Europe is needed.
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